FDA granted a Breakthrough Therapy Designation to Lenvima (lenvatinib) in patients with advanced or metastatic renal cell carcinoma who were previously treated with a vascular endothelial growth factor-targeted therapy.
THOMAS LYNCH JR., director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale-New Haven, will leave Yale in August to become chairman and chief executive officer of the Massachusetts General Physicians Organization.
Emma Whitehead was a six-year-old girl battling relapsed leukemia for the third time when her parents were told she had run out of treatments. Her doctors offered one last hope—enrollment in a clinical trial at Children's Hospital of Philadelphia in a completely new immunotherapy. It was a phase I toxicity trial for both children and adult patients, and few patients on phase I trials are ever cured. But Emma's family was given the miracle they had prayed for. Five years later, Emma is now a happy, healthy, 11-year-old girl who likes to play piano and soccer. Emma is cured.
The Dan L. Duncan Cancer Center at Baylor College of Medicine and the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai received NCI designations this week.
Here is what Hagop Kantarjian has learned over the past two years of his campaign to lower the prices of cancer drugs:People would rather avoid disputing you head-on.
Many people are studying the rising prices of cancer drugs. A growing group of oncologists want to do something different: they want to give them a downward push.
MD Anderson Cancer Center has once again assumed its place at the top of the influential U.S. News & World Report rankings for 2015-2016.
The Department of Defense is taking applications for its Horizon Award, which offers up to $75,000 in funding to support junior-level scientists to conduct impactful research with the mentorship of an experienced cancer researcher.
Last week, the Centers for Medicare & Medicaid Services announced plans to support Medicare beneficiaries by reimbursing doctors for advance care planning beginning in January 2016.
MD Anderson Cancer Center's faculty has asked the UT System to freeze the salaries of Ronald DePinho and members of his executive team until they reach a level of parity with faculty salaries, according to a white paper presented to UT System Chancellor Bill McRaven June 14.
